The natural agonist of PPARα, PEA, has anti-inflammatory properties, but there have been no clinical trials on its effects on the course of IBD; however, there is a pilot phase IIb RCT on its use in irritable bowel syndrome (IBS). This evidence concerns the gene PPARA and irritable bowel syndrome.